RT Journal Article
T1 Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension.
A1 Morales Cano, Daniel
A1 Barreira Barba, Bianca
A1 Olaiz Navarro, Beatriz De
A1 Callejo Arranz, María
A1 Mondejar Parreño, Gema
A1 Esquivel Ruiz, Sergio Antonio
A1 Lorente, José Ángel
A1 Moreno Gutiérrez, Laura
A1 Barberá, Joan Albert
A1 Cogolludo Torralba, Ángel Luis
A1 Pérez Vizcaíno, Francisco
AB Current approved therapies for pulmonary hypertension (PH) aim to restore the balance between endothelial mediators in the pulmonary circulation. These drugs may exert vasodilator effects on poorly oxygenated vessels. This may lead to the derivation of blood perfusion towards low ventilated alveoli, i.e., producing ventilation-perfusion mismatch, with detrimental effects on gas exchange. The aim of this study is to analyze the oxygen-sensitivity in vitro of 25 drugs currently used or potentially useful for PH. Additionally, the study analyses the effectiveness of these vasodilators in the pulmonary vs. the systemic vessels. Vasodilator responses were recorded in pulmonary arteries (PA) and mesenteric arteries (MA) from rats and in human PA in a wire myograph under different oxygen concentrations. None of the studied drugs showed oxygen selectivity, being equally or more effective as vasodilators under conditions of low oxygen as compared to high oxygen levels. The drugs studied showed low pulmonary selectivity, being equally or more effective as vasodilators in systemic than in PA. A similar behavior was observed for the members within each drug family. In conclusion, none of the drugs showed optimal vasodilator profile, which may limit their therapeutic efficacy in PH.
PB MDPI
SN 2076-3921
YR 2021
FD 2021-01-21
LK https://hdl.handle.net/20.500.14352/7426
UL https://hdl.handle.net/20.500.14352/7426
LA eng
NO Morales Cano, D., Barrerira Barba, B., Olaiz Navarro, B. et al. «Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension». Antioxidants, vol. 10, n.o 2, enero de 2021, p. 155. Crossref, https://doi.org/10.3390/antiox10020155.
NO European Union
NO Ministerio de Economía, Comercio y Empresa (España)
NO Instituto de Salud Carlos III
NO Fundación contra la Hipertensión Pulmonar
NO Universidad Complutense de Madrid
NO Ministerio de Educación, Formación Profesional y Deportes (España)
DS Docta Complutense
RD 27 sept 2024